Efficacy and safety of Metformin and Huanglian

- Sow Li Ying, Lim Yuen Shan, Lim Minqi

Type 2 diabetes mellitus (T2DM) is a global metabolic disorder characterized by insulin resistance and chronic hyperglycemia. According to the National Population Health Survey 2023-2024, the prevalence of diabetes among Singapore residents aged 18 to 74 years was 9.1%, with a marked ethnic disparity of 7.4% in Chinese, 15.0% in Malays, and 15.5% in Indians, corresponding to an approximately two-fold higher risk in the latter two groups. Metformin remains the primary first-line oral monotherapy; however, gastrointestinal adverse effects affect roughly 30% of patients, and lactic acidosis, although rare (approximately 1 in 30,000), is potentially fatal. Glycemic control also remains suboptimal, with two in three known diabetic individuals who underwent health screening failing to meet target levels. In Traditional Chinese Medicine (TCM), Huanglian (Rhizoma Coptidis) has long been used to clear heat, dry dampness and to manage diabetic syndromes (xiaoke). Its principal bioactive alkaloid, berberine, has demonstrated antibacterial, anti-inflammatory, antioxidant, antidiabetic, and anticancer properties in numerous studies.

Metformin and berberine exert complementary pharmacodynamic effects, partly through convergent activation of AMP-activated protein kinase (AMPK). This pathway suppresses hepatic gluconeogenesis, enhances skeletal muscle glucose uptake through glucose transporter 4 (GLUT4) translocation, and improves overall insulin sensitivity. Beyond AMPK-mediated effects, berberine may confer additional metabolic benefits by attenuating pancreatic β-cell ferroptosis under hyperglycaemic conditions, suppressing pro-inflammatory signalling pathways and mediators (including NF-κB, TNF-α, and IL-6), inhibiting intestinal dipeptidyl peptidase-4 (DPP-4) activity, and regulation of gut microbiota. From a pharmacokinetic perspective, berberine competitively inhibits organic cation transporters 1 and 2 (OCT1 and OCT2) and multidrug and toxin extrusion protein 1 (MATE1), which collectively contribute to metformin transport and disposition. Although co-administration modestly reduces plasma metformin concentrations, hepatic and renal tissue concentrations remain largely unchanged or may increase, suggesting preserved tissue exposure and potentially maintained pharmacological efficacy despite reduced systemic exposure. The absence of increased plasma metformin concentrations also suggests that berberine co-administration is unlikely to exacerbate metformin-associated lactic acidosis risk through increased systemic drug exposure. Nevertheless, berberine exhibits moderate inhibitory activity against cytochrome P450 2D6 (CYP2D6; IC₅₀ = 7.40 μM), highlighting the potential for pharmacokinetic drug–drug interactions with concomitantly administered CYP2D6 substrates.

Clinical evidence suggests that adding Huanglian or berberine to metformin improves glycaemic and lipid control compared with metformin monotherapy. In a long-term retrospective cohort, high-dose Rhizoma Coptidis extract granules (≥0.08 g/kg/day) were associated with significant reductions in HbA1c, fasting plasma glucose (FPG), and total cholesterol over 60 weeks, with no evident hepatic or renal toxicity. Meta-analyses of 33 randomised controlled trials (RCTs; n = 2,846) of Huanglian-containing formulas (e.g. Gegen Qinlian Decoction) and 50 RCTs of berberine reported statistically significant reductions in FPG, 2-hour postprandial glucose (2hPG), and HbA1c with combination therapy relative to metformin alone.

In conclusion, co-administration of metformin with Huanglian or berberine appears to be an effective and well-tolerated adjunctive strategy for T2DM management. Staggering administration times may be clinically advised to minimise competition for intestinal transport. Further standardized, multi-center RCTs are recommended to establish dosing guidelines and evaluate long-term outcomes.

References

  1. Duncan, B. B., Magliano, D. J., & Boyko, E. J. (2026). IDF diabetes atlas 11th edition 2025: global prevalence and projections for 2050. Nephrology Dialysis Transplantation, 41(1), 7-9.
  2. Ministry of Health Singapore. (2026). National Population Health Survey 2025 report. https://isomer-user-content.by.gov.sg/3/6d240639-e156-403e-bb26-1bdddfe0af6f/NPHS%202025%20Survey%20Report_Final.pdf
  3. Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012). Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics, 22(11), 820.
  4. Wu, X., Li, Q., Xin, H., Yu, A., & Zhong, M. (2005). Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. European Journal of Clinical Pharmacology, 61(8), 567-572.
  5. Zhao, Y., Hellum, B. H., Liang, A., & Nilsen, O. G. (2012). The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine. Phytotherapy Research, 26(2), 277-283.
  6. Kwon, M., Choi, Y. A., Choi, M. K., & Song, I. S. (2015). Organic cation transporter-mediated drug–drug interaction potential between berberine and metformin. Archives of Pharmacal Research, 38(5), 849-856.
  7. Oyanna, V. O., Garcia-Torres, K. Y., Bechtold, B. J., Lynch, K. D., Call, M. R., Horváth, M., … & Clarke, J. D. (2023). Goldenseal-mediated inhibition of intestinal uptake transporters decreases metformin systemic exposure in mice. Drug Metabolism and Disposition, 51(11), 1483-1489.
  8. Nguyen, J. T., Tian, D. D., Tanna, R. S., Hadi, D. L., Bansal, S., Calamia, J. C., … & Paine, M. F. (2021). Assessing transporter‐mediated natural product‐drug interactions via in vitro‐in vivo extrapolation: clinical evaluation with a probe cocktail. Clinical Pharmacology & Therapeutics, 109(5), 1342-1352.
  9. Huang, Y. H., Liu, G. H., Hsu, T. Y., Yang, L. Y., Lee, M. C., Huang, C. T., & Wu, Y. H. (2021). Effective dose of Rhizoma Coptidis extract granules for type 2 diabetes treatment: a hospital-based retrospective cohort study. Frontiers in Pharmacology, 11, 597703.
  10. Pan, L., Zhai, X., Duan, Z., Xu, K., & Liu, G. (2022). Systematic review and meta-analysis of Coptis chinensis Franch.-containing traditional Chinese medicine as an adjunct therapy to metformin in the treatment of type 2 diabetes mellitus. Frontiers in Pharmacology, 13, 956313.
  11. Wang, J., Bi, C., Xi, H., & Wei, F. (2024). Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1455534.

Click to download PowerPoint

Share
Scroll to Top

Menu

Scam Alert Notice